STING1 and neoplasm: Deng Rong’s team validated through clinical samples and humanized mouse models that combining STING agonists (e.g., ADU-S100) with AKT inhibitors (e.g., Capivasertib) breaks this cycle, significantly suppressing resistant tumor growth and promoting CD8+ T-cell infiltration, thereby converting “cold tumors” into “hot tumors”.